Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis

BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is complicated by fibrosis and comorbid conditions. We investigated the real-world burden of fibrosis and additional cardiovascular renal and metabolic (CVRM) comorbidities on health-related quality of life (HRQoL) and healthcare resource utilization. METHODS: Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024. Physicians reported patient demographics and clinical characteristics. Patients voluntarily self-reported disease burden via the EQ-5D-5L and the Work Productivity and Activity Impairment (WPAI) questionnaire. Patients were grouped as: early fibrosis (stage 0-2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3-4) with additional CVRM comorbidities (AFwC). Outcomes between groups were compared statistically, with p